| Imipenem/cilastatin therapy for serious bacterial infections. | |
| | |
MedLine Citation:
|
PMID: 3901214 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Imipenem was administered intravenously with cilastatin to patients with suspected or documented significant infections. The mean peak serum level of imipenem 30 min after infusion of a 500 mg dose was 18.4 micrograms/ml, and the mean trough level (30 min before infusion) was 2.4 micrograms/ml. The organisms isolated before therapy included Enterobacteriaceae, Staphylococcus aureus, streptococci, Pseudomonas aeruginosa, and anaerobes. The response rate in 25 assessable patients was 96%, with 40% experiencing a complete cure and 56% improvement. Therapy failed in only one instance because an isolate of P. aeruginosa was mistakenly reported to be susceptible on disk testing. Toxicity in the 33 patients treated was generally minimal and included phlebitis, mild liver function abnormalities, eosinophilia, and thrombocytosis. The emergence of resistant organisms during therapy was very uncommon. Imipenem/cilastatin is a promising agent for the treatment of complicated infections. |
| | |
Authors:
|
D M Nielsen; J R Katz; R D AhLoy; R S Hansen; R D Meyer |
Related Documents
:
|
11583754 - Effect of inhaled tobramycin on early pseudomonas aeruginosa colonisation in patients w... 2587954 - The etiology of bacterial cellulitis as determined by fine-needle aspiration. 17542774 - A febrile neutropenic patient with enterococcus gallinarum sepsis treated with daptomyc... 11961874 - Chronic suppurative otitis media in a children's hospital in addis ababa, ethiopia. 3473654 - Serological profiles in subgroups of patients with sjögren's syndrome. 8395554 - Changes in the prevalence of hepatitis b and c infection in patients with hepatocellula... |
Publication Detail:
|
Type: Clinical Trial; Journal Article |
Journal Detail:
|
Title: Reviews of infectious diseases Volume: 7 Suppl 3 ISSN: 0162-0886 ISO Abbreviation: Rev. Infect. Dis. Publication Date: 1985 Jul-Aug |
Date Detail:
|
Created Date: 1985-11-04 Completed Date: 1985-11-04 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7905878 Medline TA: Rev Infect Dis Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: S506-12 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Bacterial Infections / blood, drug therapy* Cilastatin Clinical Trials as Topic Cyclopropanes / administration & dosage*, adverse effects, blood Drug Resistance, Microbial Drug Therapy, Combination Female Humans Imipenem Male Middle Aged Phlebitis / chemically induced Respiratory Tract Infections / drug therapy Sepsis / drug therapy Thienamycins / administration & dosage*, adverse effects, blood Urinary Tract Infections / drug therapy |
| Chemical | |
Reg. No./Substance:
|
0/Cyclopropanes; 0/Thienamycins; 74431-23-5/Imipenem; 82009-34-5/Cilastatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Open trial of imipenem/cilastatin therapy for serious bacterial infections.
Next Document: Imipenem/cilastatin in the treatment of intraabdominal infections: a review of worldwide experience.